Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines

Transplantation

Volumn 69, Issue 9, 2000, Pages 1977-1981

  Blaheta, Roman A ^a,c   Nelson, Karen ^a   Oppermann, Elsie ^a   Leckel, Kerstin ^a   Harder, Sebastian ^a   Cinatl, Jindrich ^a   Weber, Stephan ^a   Shipkova, Maria ^b   Encke, Albrecht ^a   Markus, Bernd H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; MIBEFRADIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTAGLANDIN E2; TACROLIMUS; VERAPAMIL;

ALLOGRAFT; ARTICLE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0034657317     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00044     Document Type: Article

References (16)

1. 2 primes naive T cells for the production of anti-inflammatory cytokines. Eur J Immunol 1997; 27: 3526.
2. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108.
3. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150: 5321.
4. Thamer M, Chan JK, Ray NF, Vassalotti JA, Kimmel PL. Drug use concomitant with cyclosporine immunosuppressive therapy for 3 years after renal transplantation. Am J Kidney Dis 1998; 31: 283.
5. Zanker B, Marx S, Strom TB, Kohler H. The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes. Int J Immunopharmacol 1994; 16: 507.
6. Blaheta RA, Hailer NP, Brude N, et al. Novel mode of action of the calcium antagonist mibefradil (Ro 40-5967): potent immunosuppression by inhibition of T-cell infiltration through allogeneic endothelium. Immunology 1998; 94: 213.
7. Birx DL, Berger M, Fleischer TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984; 133: 2904.
8. Pennington M, Kemmerich B, Kazanjian PH, Marsh JD, Boerth LW. Verapamil impairs human neutrophil chemotaxis by a non-calcium-mediated mechanism. J Lab Clin Med 1986; 108: 44.
9. Li T, Izumi R, Shimizu K. The immunosuppressive effect of a leukotriene B4 receptor antagonist on liver allotransplantation in rats. Surg Today 1996; 26: 419.
10. 2 derived from Kupffer cells. Transplantation 1999; 68: 440.
11. Perez RV, Johnson J, Hubbard NE, et al. Selective targeting of Kupffer cells with liposomal butyrate augments portal venous transfusion-induced immunosuppression. Transplantation 1998; 65: 1294.
12. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 1999; 8: 900.
13. Perez RV, Swanson C, Morgan M, Erickson K, Hubbard NE, German JB. Portal venous transfusion up-regulates Kupffer cell cyclooxygenase activity: a mechanism of immunosuppression in organ transplantation. Transplantation 1997; 64: 135.
14. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc 1991; 23: 10.
15. The Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507.
16. Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients. Transplantation 1998; 66: 1395.